Lonza Group AG
LONNBiotechnology
CHF 640.80+1.75%As of Oct 29vs prior close
- Market cap
- $54B
- P/E (TTM)
- –
- P/E (FY1)
- 34.3×
- From 52W high
- 0.00%
- EPS (LTM)
- CHF 15.09
- Revenue (LTM)
- CHF 6.9B
- Net margin
- -1.60%
- Dividend yield
- 0.78%
Nomior Score
60
Steady ProfileTop 26% of the scored universe
Growth63
Quality61
Value45
Momentum55
Resilience60
Growth
+1.62%revenue a year over 3 fiscal years
YE22 CHF 6.2BLTM CHF 6.9B
Connections
Revenue to profitYE25
The net loss was 4% of revenue, wider by 16 pts on a year.